GLP Watchdog

Layla vs RxSpan MD

Neither Layla nor RxSpan MD has an FDA warning letter on record. On brand-name tirzepatide pen, RxSpan MD costs $3,960 less a year at standing rates: $1,069 a month against $1,399 a month at Layla. It is one of two products the two sell at comparable terms.

By Ruth Calder · Enforcement Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed

The record

Layla / RxSpan MD

Layla logo

Layla

6.8/10

Featured pick (affiliate partner)

RxSpan MD logo

RxSpan MD

7.9/10

FDA warning letters
None on record
None on record
Pharmacy
None named in our record
Lowest standing price
$237/moCompounded oral semaglutide
$249/moCompounded semaglutide injection
States
No state list published
All 50 states
Checked
Prices captured Record checked October 2026
Prices captured Record checked October 2026
Visit LaylaFull review
Visit RxSpan MDFull review

RxSpan MD is our featured pick on this page because it is an affiliate partner: we are paid if you sign up through our link. Layla pays us nothing. The scores are computed the same way for both and are shown as computed (Layla 6.8, RxSpan MD 7.9). How we are paid

What the record shows

  1. 01

    Neither Layla nor RxSpan MD has an FDA warning letter on record.

  2. 02

    RxSpan MD names four pharmacies. Layla names no compounding pharmacy in our record.

  3. 03

    On brand-name tirzepatide pen, RxSpan MD costs $3,960 less a year at standing rates: $1,069 a month against $1,399 a month at Layla. It is one of two products the two sell at comparable terms.

  4. 04

    Only Layla lists a price for compounded oral semaglutide. Only RxSpan MD lists a price for compounded semaglutide injection and compounded tirzepatide injection.

  5. 05

    RxSpan MD lists all 50 states. Layla publishes no state list.

Prices and terms, product by product

A price is set against the other side only for the same product, and only when both are standing monthly or 4-week rates. Those pairs are compared by yearly cost.

Layla

RxSpan MD

Brand-name semaglutide pen

$1,399/mo

$16,788 a year

$1,299/moLower

$15,588 a year

Brand-name tirzepatide pen

$1,399/mo

$16,788 a year

$1,069/moLower

$12,828 a year

Compounded semaglutide injection
Not sold or not priced

$249/mo

$2,988 a year

Compounded tirzepatide injection
Not sold or not priced

$329/mo

$3,948 a year

Compounded oral semaglutide

$237/mo

$2,844 a year

Not sold or not priced
Price includes
Medication, clinician visits, shipping
Medication, clinician visits, shipping, coaching
Cancel any time
Yes, stated
Yes, stated
Minimum term
None; 30 days' notice
None
Refunds
If a sent prescription order can be canceled, a $100 visit and clinical fee is kept
Not stated
Early-exit fee
None stated
None stated

Read off each seller’s own pages. Layla: October 17, 2026. RxSpan MD: October 17, 2026. Every plan and dose we hold is on the full review.

The case for each

The case for Layla

6.8/10
  • Sells compounded oral semaglutide, which RxSpan MD does not price
  • Names no compounding pharmacy
  • Publishes no state list
Visit Layla

The case for RxSpan MD

7.9/10
Featured pick (affiliate partner)
  • $1,200 a year less on brand-name semaglutide pen
  • $3,960 a year less on brand-name tirzepatide pen
  • Sells compounded semaglutide injection and compounded tirzepatide injection, which Layla does not price
  • Names its compounding pharmacy
Visit RxSpan MD

Scores

Layla 6.8 · RxSpan MD 7.9 out of 10. Six weighted parts.

Value25%

3.7A
vs
B
3.4

Effectiveness25%

10.0A
vs
B
10.0

User Experience15%

8.0A
vs
B
8.0

Trust & Safety15%

6.5A
vs
B
10.0

Accessibility10%

5.0A
vs
B
10.0

Support10%

7.0A
vs
B
8.5

The score is the same formula for every seller. Payment does not enter it. Method

Layla vs RxSpan MD: questions

Neither Layla nor RxSpan MD has an FDA warning letter on record. Letters are matched to a seller by company, domain and address, never by a similar name.
RxSpan MD names four pharmacies. Layla names no compounding pharmacy in our record. A 503A pharmacy compounds for named patients on a prescription; a 503B outsourcing facility is registered with FDA and inspected under federal manufacturing rules.
RxSpan MD, by $1,200 a year at standing rates. Layla: $1,399 a month, about $16,788 a year. RxSpan MD: $1,299 a month, about $15,588 a year.
Layla states you can cancel at any time; refunds: if a sent prescription order can be canceled, a $100 visit and clinical fee is kept. RxSpan MD states you can cancel at any time.
RxSpan MD is our featured pick on this page because it is an affiliate partner: we are paid if you sign up through our link. Layla pays us nothing. The scores are computed the same way for both and are shown as computed (Layla 6.8, RxSpan MD 7.9).

Other sellers we are paid by

Affiliate partners outside this pair. Each has its own record and review, scored the same way.

Sellers closest to these two

Matched on molecule, form and price. Every pair we list · The register

Brand names on this page are registered marks. Novo Nordisk holds Wegovy®, Ozempic® and Rybelsus®; Eli Lilly holds Zepbound®, Mounjaro® and Foundayo®. Neither company has any tie to GLP Watchdog. Trademarks